Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications

Nephrology

Volumn 16, Issue 3, 2011, Pages 261-268

  Damasiewicz, Matthew J ^a   Toussaint, Nigel D ^a   Polkinghorne, Kevan R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

chronic kidney disease; CKD MBD; FGF 23; phosphate metabolism; vitamin D

Indexed keywords

BIOLOGICAL MARKER; CALCITRIOL; CALCIUM CARBONATE; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER;

ARTERIAL STIFFNESS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; FEEDBACK SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CALCITRIOL; CHRONIC DISEASE; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS;

EID: 79951980332     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01443.x     Document Type: Review

References (68)

1. Foley RN, Parfrey PS, Sarnak MJ,. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112-19. (Pubitemid 28527268)
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK,. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 1998; 31: 607-17.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM,. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004; 15: 2208-18. (Pubitemid 39031360)
4. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-87. (Pubitemid 41623345)
5. Bhan I, Thadhani R,. Vascular calcification and ESRD: A hard target. Clin. J. Am. Soc. Nephrol. 2009; 4 (Suppl 1): S102-5.
6. Consortium ADHR,. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat. Genet. 2000; 26: 345-8.
7. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 2001; 98: 6500-505. (Pubitemid 32488266)
8. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004; 113: 561-8. (Pubitemid 38542505)
9. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B,. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005; 14: 385-90. (Pubitemid 40220655)
10. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006; 38: 1310-15. (Pubitemid 44646294)
11. Yamashita T,. Structural and biochemical properties of fibroblast growth factor 23. Ther. Apher. Dial. 2005; 9: 313-18. (Pubitemid 41800800)
12. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003; 112: 683-92. (Pubitemid 38057709)
13. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-74. (Pubitemid 44949607)
14. Khosravi A, Cutler CM, Kelly MH, et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 2007; 92: 2374-7. (Pubitemid 46997149)
15. Seiler S, Heine GH, Fliser D,. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int. Suppl. 2009; 114: S34-42.
16. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 2010; 95: 578-85.
17. Gaasbeek A, Meinders AE,. Hypophosphatemia: An update on its etiology and treatment. Am. J. Med. 2005; 118: 1094-101. (Pubitemid 41362606)
18. Razzaque MS,. FGF23-mediated regulation of systemic phosphate homeostasis: Is Klotho an essential player? Am. J. Physiol. Renal. Physiol. 2009; 296: F470-76.
19. Kowarski S, Schachter D,. Effects of vitamin D on phosphate transport and incorporation into mucosal constituents of rat intestinal mucosa. J. Biol. Chem. 1969; 244: 211-17.
20. Forster IC, Hernando N, Biber J, Murer H,. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int. 2006; 70: 1548-59. (Pubitemid 44606989)
21. Baum M, Schiavi S, Dwarakanath V, Quigley R,. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005; 68: 1148-53. (Pubitemid 43246431)
22. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004; 19: 429-35. (Pubitemid 38787398)
23. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51. (Pubitemid 27494749)
24. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006; 281: 6120-23. (Pubitemid 43847540)
25. Tohyama O, Imura A, Iwano A, et al. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J. Biol. Chem. 2004; 279: 9777-84. (Pubitemid 38372575)
26. Larsson TE,. The role of FGF-23 in CKD-MBD and cardiovascular disease: Friend or foe? Nephrol. Dial. Transplant. 2010; 25: 1376-81.
27. Perwad F, Zhang MY, Tenenhouse HS, Portale AA,. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am. J. Physiol. Renal. Physiol. 2007; 293: F1577-83. (Pubitemid 350085994)
28. Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am. J. Physiol. Endocrinol. Metab. 2005; 288: E1101-9. (Pubitemid 40726796)
29. Kolek OI, Hines ER, Jones MD, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 289: G1036-42. (Pubitemid 41740608)
30. Antoniucci DM, Yamashita T, Portale AA,. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006; 91: 3144-9. (Pubitemid 44271770)
31. Isakova T, Gutierrez O, Shah A, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008; 19: 615-23. (Pubitemid 351355405)
32. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB,. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-9. (Pubitemid 37449564)
33. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006; 70: 2141-7. (Pubitemid 44871378)
34. Shirley DG, Faria NJ, Unwin RJ, Dobbie H,. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol. Dial. Transplant. 2010; 25: 3191-5.
35. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 2001; 280: 1015-20. (Pubitemid 32924441)
36. Farrow EG, Davis SI, Summers LJ, White KE,. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 2009; 20: 955-60.
37. Ix JH, Shlipak MG, Wassel CL, Whooley MA,. Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study. Nephrol. Dial. Transplant. 2010; 25: 993-7.
38. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 2792-6.
39. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600-8.
40. Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 2007; 18: 2683-8. (Pubitemid 47531195)
41. Liu S, Quarles LD,. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007; 18: 1637-47. (Pubitemid 46870300)
42. Evenepoel P, Meijers B, Viaene L, et al. Fibroblast growth factor-23 in early chronic kidney disease: Additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 2010; 5: 1268-76.
43. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 2205-15. (Pubitemid 41716454)
44. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D,. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150: 4835-45.
45. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K,. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-8.
46. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004-13. (Pubitemid 47530570)
47. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R,. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003; 349: 446-56. (Pubitemid 36910023)
48. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J. Am. Soc. Nephrol. 2005; 16: 1115-25. (Pubitemid 41710323)
49. Wald R, Sarnak MJ, Tighiouart H, et al. Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am. J. Kidney Dis. 2008; 52: 531-40.
50. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2008; 52: 519-30.
51. Avram MM, Mittman N, Myint MM, Fein P,. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am. J. Kidney Dis. 2001; 38: 1351-7. (Pubitemid 34193126)
52. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-130.
53. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-92.
54. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005; 67: 1171-8. (Pubitemid 41623344)
55. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix gla protein with mortality in coronary artery disease: The heart and soul study. Ann. Intern. Med. 2010; 152: 640-48.
56. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
57. Mirza MA, Larsson A, Lind L, Larsson TE,. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-90.
58. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant. 2009; 24: 3125-31.
59. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos. Int. 2006; 17: 1506-13. (Pubitemid 44387485)
60. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE,. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-51.
61. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD,. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 2010; 5: 110-16.
62. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 2010; 5: 286-91.
63. Koiwa F, Kazama JJ, Tokumoto A, et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 2005; 9: 336-9. (Pubitemid 41800805)
64. Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 2009; 20: 388-96.
65. Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin. J. Am. Soc. Nephrol. 2008; 3: 1829-36.
66. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y,. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 2007; 7: 1193-200. (Pubitemid 46643105)
67. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int. 2006; 70: 1486-94. (Pubitemid 44527320)
68. Serra AL, Wuhrmann C, Wuthrich RP,. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am. J. Kidney Dis. 2008; 52: 1151-7.